Compare Johnson & Johnson (JNJ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Johnson & Johnson (JNJ) trades at $248.61, down 5.73% over 24 hours, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 67.91% gross margins and 21.48% net income margin, though valuation ratios appear elevated with a P/E of 38.59. Recent earnings show consistent beats except for Q4 2025, with Q3 2026 EPS of $2.59 exceeding expectations. Analyst consensus remains positive with a $282.53 price target, representing 13.6% upside potential from current levels.

JNJ's diversified healthcare portfolio and robust dividend history provide stability, while innovation in pharmaceuticals and medical technology drives growth. Key risks include patent expirations, regulatory challenges, and increasing debt levels. The stock offers defensive characteristics with upside potential from pipeline developments, though current valuation requires careful monitoring of execution against growth expectations.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.